Researchers found that peripheral injections of etanercept normalize the depressive effects of repeated steroid administration in an animal model.
There is a strong connection between the immune system and the brain in the context of depression. Chronic stress induces an inflammatory response in the body, which in the central nervous system includes an increase in pro-inflammatory cytokines. A recent study investigated whether peripheral injections of the anti—tumor necrosis factor (anti-TNF) inhibitor etanercept can help treat depression.
The study was conducted in an animal model comprising 24 male Long-Evans rats. The rats were randomly assigned to one of the following treatment groups:
All steroid and vehicle injections were administered once a day subcutaneously for 21 consecutive days. Etanercept and saline injections were given subcutaneously twice per week for 21 days. In addition, behavioral tests were conducted in the form of a forced swim test, an object-recognition memory test, and an object-in-place paradigm test.
The results of the experiment show that prolonged exposure to steroids produces a cluster of effects characterized by increased immobility in the swim test, impaired spatial memory on the object location and object-in-place tests, and reduced hippocampal neurogenesis. However, semi-weekly etanercept giving concurrently with steroids prevented all of these effects, which suggested that anti-TNF drugs could have a role in treating depression.
A particularly noteworthy finding of the study was that peripheral administration of etanercept restored steroid-induced deficits in hippocampal neurogenesis. However, the role of hippocampal neurogenesis in depression is a controversial issue, as the removal of hippocampal neurogenesis does not always induce depression-like behavior, and antidepressant effects can be seen without increases in neurogenesis.
The study also found that peripheral injections of etanercept normalize steroid-induced deficits in hippocampal reelin (a glycoprotein) expression. This idea comes from previous observations that reelin-overexpressing mice have increased neurogenesis, and that exogenous reelin can recover cognitive deficits in mouse models of both Angelman syndrome and Alzheimer disease. These observations correlate with the findings of this study that etanercept restores both object-location and object-in-place memory.
The researchers found that peripheral injections of etanercept normalize the depressive effects of repeated steroid administration. These results add to previous studies that suggested inflammatory events are a critical component of the pathogenesis of depression, and that there could be a key link between the immune system and the brain.
Reference
Brymer K, Fenton E, Kalychuk L, Caruncho H. Peripheral etanercept administration normalizes behavior, hippocampal neurogenesis, and hippocampal reelin and GABAA receptor expression in a preclinical model of depression [published online February 20, 2018]. Front Pharmacol. doi:10.3389/fphar.2018.00121.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Sustainable Biosimilar Markets Achieve Widespread Market Uptake Through Collective Action
April 22nd 2024Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that applying collective action theory can achieve widespread biosimilar market uptake by fostering collaboration for long-term benefits.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.